Lichen planus erosivus L43.8

Bullous changes in the lichen planus between the toes and on the soles of the feet that lead to painful erosions. S.a.u. Lichen planus ulcerosus. From a clinical point of view it is not necessary to distinguish between a lichen planus erosivus of the skin and a lichen planus ulcerosus of the skin, as only gradual differences of a similar pathological-anatomical process take place.

Systemic therapy is usually necessary. See below Lichen planus.

There are individual reports of positive effects of upadacitinib (Balestri R et al. 2022) and apremilast (Chessa MA et al. 2019).

Several case reports and case series have reported on the safety and efficacy of tofacitinib (6 articles), baricitinib (4 articles) and ruxolitinib (1 article). The predominant variants in which these JAK inhibitors produced improvement were lichen planopilaris, nail LP and erosive lichen planus (Motamed-Sanaye A et al. 2022).

1. Balestri R et al. (2022) Treatment of Oral Erosive Lichen Planus With Upadacitinib. JAMA Dermatol 158: 457-458.
2. Chessa MA et al. (2019) Erosive lichen planus: beyond the nails. J Eur Acad Dermatol Venereol 33:e97-e99.
3. Mauskar M (2017) Erosive lichen planus. Obstet Gynecol Clin North Am 44:407-420.

4. Motamed-Sanaye A et al. (2022) JAK inhibitors in lichen planus: a review of pathogenesis and treatments. J Dermatolog Treat 33:3098-3103.